Abstract
On March 4th, 2016, Springer’s Cancer Nanotechnology office promoted the launch of the Nanotechnology Startup Challenge in Cancer (NSC2). This innovation-development model is a partnership among our company, the Center for Advancing Innovation (CAI), MedImmune, the global biologics arm of AstraZeneca, and multiple institutes at the National Institutes of Health (NIH). NSC2 “crowdsources” talent from around the world to launch startups with near-term, commercially viable cancer nanotechnology inventions, which were developed by the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI), and the National Institute of Biomedical Imaging and Bioengineering (NIBIB). Crowdsourcing is a process in which one uses the internet to engage a large group of people in an activity, such as NSC2. For this initiative, CAI engaged universities, industry professionals, foundations, investors, relevant media outlets, seasoned entrepreneurs, and life sciences membership organizations to request that they participate in the challenge. From this outreach, fifty-six key thought leaders have enrolled in NSC2 as judges, mentors, and/or advisors to challenge teams (http://www.nscsquared.org/judges.html). Along with crowdsourcing talent to bolt startups around NIH inventions, NSC2 will also catalyze the launch of companies around “third-party” cancer nanotechnology inventions, which were conceived and developed outside of the NIH. Twenty-eight robust teams were accepted to the challenge on March 14th, 2016.
Highlights
On March 4th, 2016, Springer’s Cancer Nanotechnology office promoted the launch of the Nanotechnology Startup Challenge in Cancer (NSC2)
Center for Advancing Innovation (CAI) evaluated these teams on more than forty criteria, which we developed through an analysis of successful startups
Through NSC2, twenty-four teams are competing to license eight National Institutes of Health (NIH) inventions, whereas four teams submitted their own inventions with strong commercialization potential
Summary
On March 4th, 2016, Springer’s Cancer Nanotechnology office promoted the launch of the Nanotechnology Startup Challenge in Cancer (NSC2). CAI evaluated these teams on more than forty criteria, which we developed through an analysis of successful startups. Each team has at least two currently enrolled students and one seasoned entrepreneur with more than 3 years in a startup. Through NSC2, twenty-four teams are competing to license eight NIH inventions, whereas four teams submitted their own inventions with strong commercialization potential.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have